It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We evaluated the impact of on-demand oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) on herpes simplex virus (HSV)-1/2 incidence among men who have sex with men (MSM) enrolled in the ANRS IPERGAY trial. Serum samples were tested at baseline and at the last visit for HSV-1/2 antibodies. Overall HSV-1 incidence was 11.7 per 100 person-years; 16.2 and 7.8 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .19). Overall HSV-2 incidence was 7.6 per 100 person-years; 8.1 and 7.0 per 100 person-years in the TDF/FTC and placebo arm, respectively (P = .75). On-demand oral PrEP with TDF/FTC failed to reduce HSV-1/2 incidence in this population.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM) Unité, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Institut Universitaire d’Hématologie, Sorbonne Paris Cité, Université Paris Diderot, Hôpital Saint Louis, France
2 INSERM Service Commun, Villejuif, France
3 Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France
4 Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France
5 Maladies Infectieuses, Hôpital de la Croix Rousse, Centre Hospitalier et Universitaire de Lyon, France
6 Department of Infectious Diseases, University Hospital of Nantes and Centre d’Investigation Clinique, INSERM, Nantes
7 Maladies Infectieuses, Hôpital de l’Archet, Centre Hospitalier de Nice, France
8 Maladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, France
9 Maladies Infectieuses, Centre Hospitalier de l’Université de Montréal, Canada
10 INSERM Service Commun, Villejuif, France; Université Paris-Sud, Université Paris-Saclay, France
11 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Institut Universitaire d’Hématologie, Sorbonne Paris Cité, Université Paris Diderot, Hôpital Saint Louis, France; Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France